GlassScriptPhysician profile
Jennifer Thieman
NPI 1942410527
$5,162.28
in general payments reported to CMS, 2019-2025
32 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $1,240 · 2021: $695 · 2022: $851 · 2023: $1,091 · 2024: $651 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,670.64 | 2019-2022 | |
| Abbvie INC. | $1,322.59 | 2019-2025 | Botox, Liletta, Ubrelvy |
| Myriad Women'S Health, INC. | $363.94 | 2023 | Myrisk |
| Astellas Pharma US INC | $332.66 | 2021-2025 | Veozah, Myrbetriq |
| Gynesonics, INC. | $144.30 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mayne Pharma Commercial LLC | $139.39 | 2022-2025 | |
| Therapeuticsmd, INC. | $124.18 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $108.35 | 2019-2025 | NP Thyroid 60 |
| Sumitomo Pharma America, INC. | $104.91 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $99.97 | 2021-2024 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.06 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $80.35 | 2021 | |
| Galderma Laboratories, L.P. | $54.16 | 2024 | |
| Coopersurgical, INC. | $49.22 | 2020-2024 | Paragard T 380a |
| Lupin INC. | $47.83 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $47.41 | 2022-2023 | Acessa Provu System |
| Ibsa Pharma INC. | $43.10 | 2023-2024 | Tirosint, Licart, Licart |
| Meditrina | $38.79 | 2022 | |
| Avion Pharmaceuticals | $38.63 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.62 | 2022 | |
| Scynexis, INC. | $34.37 | 2022 | |
| Evofem Biosciences, INC. | $33.28 | 2021 | |
| Lundbeck LLC | $22.99 | 2023 | Vyepti |
| Pfizer INC. | $18.28 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $16.68 | 2025 | Xdemvy |
| Romark Laboratories, Lc | $15.48 | 2020 | |
| Exact Sciences Corporation | $14.27 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $13.52 | 2022 | |
| Minerva Surgical, INC | $13.06 | 2023 | |
| Mylan Pharmaceuticals INC. | $12.73 | 2021 | |
| Dysis Medical, INC. | $11.32 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Thieman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.